CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Defined Benefit Plan, Amortization of Gain (Loss)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Defined Benefit Plan, Amortization of Gain (Loss) of -$1.21 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for the quarter ending 2021-12-25 was -$1.20M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for the quarter ending 2021-09-25 was -$1.11M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for the quarter ending 2021-06-26 was -$1.11M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for the quarter ending 2021-03-27 was -$1.11M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for fiscal 2025 was -$1.21M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for fiscal 2024 was -$1.63M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for fiscal 2023 was -$1.23M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, amortization of gain (loss) for fiscal 2022 was -$2.87M.
| Period end | Defined Benefit Plan, Amortization of Gain (Loss) 3 month | Defined Benefit Plan, Amortization of Gain (Loss) 6 month | Defined Benefit Plan, Amortization of Gain (Loss) 9 month | Defined Benefit Plan, Amortization of Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-27 | -$1.21M 10-K · filed 2026-02-18 | |||
| 2024-12-28 | -$1.63M 10-K · filed 2026-02-18 | |||
| 2023-12-30 | -$1.23M 10-K · filed 2026-02-18 | |||
| 2022-12-31 | -$2.87M 10-K · filed 2025-02-19 | |||
| 2021-12-25 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$2.31M derived: sum of 2 quarters · filed 2024-02-14 | -$3.42M derived: sum of 3 quarters · filed 2024-02-14 | -$4.53M 10-K · filed 2024-02-14 |
| 2021-09-25 | -$1.11M 10-Q · filed 2021-11-03 | -$2.22M derived: sum of 2 quarters · filed 2021-11-03 | -$3.33M 10-Q · filed 2021-11-03 | -$4.81M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | -$1.11M 10-Q · filed 2021-08-04 | -$2.22M 10-Q · filed 2021-08-04 | -$3.70M derived: sum of 3 quarters · filed 2023-02-22 | -$5.29M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | -$1.11M 10-Q · filed 2021-05-04 | -$2.59M derived: sum of 2 quarters · filed 2023-02-22 | -$4.18M derived: sum of 3 quarters · filed 2023-02-22 | -$5.76M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$3.07M derived: sum of 2 quarters · filed 2023-02-22 | -$4.65M derived: sum of 3 quarters · filed 2023-02-22 | -$6.24M 10-K · filed 2023-02-22 |
| 2020-09-26 | -$1.59M 10-Q · filed 2021-11-03 | -$3.17M derived: sum of 2 quarters · filed 2021-11-03 | -$4.76M 10-Q · filed 2021-11-03 | -$5.54M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | -$1.59M 10-Q · filed 2021-08-04 | -$3.17M 10-Q · filed 2021-08-04 | -$3.96M derived: sum of 3 quarters · filed 2022-02-16 | -$4.45M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | -$1.59M 10-Q · filed 2021-05-04 | -$2.37M derived: sum of 2 quarters · filed 2022-02-16 | -$2.86M derived: sum of 3 quarters · filed 2022-02-16 | -$3.35M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | -$784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$1.27M derived: sum of 2 quarters · filed 2022-02-16 | -$1.76M derived: sum of 3 quarters · filed 2022-02-16 | -$2.25M 10-K · filed 2022-02-16 |
| 2019-09-28 | -$489.00K 10-Q · filed 2020-10-29 | -$977.00K derived: sum of 2 quarters · filed 2020-10-29 | -$1.47M 10-Q · filed 2020-10-29 | |
| 2019-06-29 | -$488.00K 10-Q · filed 2020-08-05 | -$977.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-30 | -$489.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-29 | -$2.99M 10-K · filed 2021-02-17 | |||
| 2017-12-30 | -$3.85M 10-K · filed 2020-02-11 | |||
| 2016-12-31 | -$2.00M 10-K · filed 2019-02-13 | |||
| 2015-12-26 | -$3.20M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |